Trial Profile
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 on Cerebrospinal Fluid Biomarkers in 36 Patients With Progressive Supranuclear Palsy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Aug 2023
Price :
$35
*
At a glance
- Drugs Ezeprogind (Primary)
- Indications Progressive supranuclear palsy
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AlzProtect
- 04 Aug 2023 Planned End Date changed from 16 Jul 2022 to 1 Jul 2024.
- 04 Aug 2023 Status changed to active, no longer recruiting.
- 20 Jul 2023 Results assessing the safety, tolerability and pharmacokinetics of AZP2006 in progressive supranuclear palsy patients, presented at the Alzheimer's Association International Conference 2023.